A phase II study of naloxone nasal spray for the treatment of opioid overdose reversal
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2016
At a glance
- Drugs Naloxone (Primary)
- Indications Opioid abuse
- Focus Registrational; Therapeutic Use
- 09 Jun 2016 According to a Lightlake therapeutics media release, the company plans to report top-line results of this trial in H1 2017.
- 06 May 2016 According to a Adapt Pharma Limited media release, the company has done a new drug submission (NDS) of naloxone nasal spray to Health Canada for the emergency reversal of opioid overdose.
- 19 Nov 2015 According to a Adapt Pharma Limited media release, the U.S. Food and Drug Administration (FDA) has approved NARCAN (naloxone hydrochloride) Nasal Spray for the emergency treatment of known or suspected opioid overdose.